For these reasons, in this paper we focused on the role of MetfDeca as a potential new drug for the treatment of DM (and related disorders) and its toxicity effects in rat models of hyperglycemia, both requesting insulin and insulin-independent, since they are altered in the metabolism of carbohydrates and lipids. Here, INS is linked to Hyperglycemia.